Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
Background: The use of somatostatin analogues (SSAs) has not been formally approved in pulmonary neuroendocrine tumours (NETs) in the absence of positive controlled trials, even though it is recommended as a potential therapeutic option in recent guidelines. Patients and methods: We have assessed th...
Main Authors: | Kiesewetter, B. (Author), Kretschmer-Chott, E. (Author), Mayerhoefer, M.E (Author), Mazal, P. (Author), Raderer, M. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier B.V.
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Neuroendocrine Tumours: a Literature Review
by: K. V. Menshikov, et al.
Published: (2021-05-01) -
Somatostatin analogues therapy in gastroenteropancreatic neuroendocrine tumours: current aspects and new perspectives
by: Roberto eBaldelli
Published: (2014-02-01) -
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
by: Anna Kathrin Stueven, et al.
Published: (2019-06-01) -
Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
by: Sheila D. Rustgi, et al.
Published: (2021-05-01) -
Intraoperative carcinoid syndrome during small-bowel neuroendocrine tumour surgery
by: Myrtille Fouché, et al.
Published: (2018-11-01)